Clinical Trial Update: AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial update for AeroVanc in MRSA-infected cystic fibrosis patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Methicillin-resistant Staphylococcus Aureus Infection

Drugs mentioned

• AeroVanc (telavancin? wait no; AeroVanc is an inhaled vancomycin formulation)

Snippet

Sponsor: Savara Inc. | Conditions: MRSA, Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2021-11-05